Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018-2022, University of Siena, via Aldo Moro 2, 53100, Siena, Italy.
J Med Chem. 2020 Nov 25;63(22):13466-13513. doi: 10.1021/acs.jmedchem.0c01049. Epub 2020 Sep 15.
Toll-like receptors (TLRs) are a class of proteins that recognize pathogen-associated molecular patterns (PAMPs) and damaged-associated molecular patterns (DAMPs), and they are involved in the regulation of innate immune system. These transmembrane receptors, localized at the cellular or endosomal membrane, trigger inflammatory processes through either myeloid differentiation primary response 88 (MyD88) or TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling pathways. In the last decades, extensive research has been performed on TLR modulators and their therapeutic implication under several pathological conditions, spanning from infections to cancer, from metabolic disorders to neurodegeneration and autoimmune diseases. This Perspective will highlight the recent discoveries in this field, emphasizing the role of TLRs in different diseases and the therapeutic effect of their natural and synthetic modulators, and it will discuss insights for the future exploitation of TLR modulators in human health.
Toll 样受体(TLRs)是一类能够识别病原体相关分子模式(PAMPs)和损伤相关分子模式(DAMPs)的蛋白质,它们参与了固有免疫系统的调节。这些位于细胞膜或内体膜上的跨膜受体,通过髓样分化初级反应 88(MyD88)或 TIR 结构域包含衔接子诱导干扰素-β(TRIF)信号通路触发炎症反应。在过去的几十年中,人们对 TLR 调节剂及其在多种病理条件下的治疗意义进行了广泛的研究,涵盖了从感染到癌症、从代谢紊乱到神经退行性变和自身免疫性疾病等多个领域。本观点将重点介绍该领域的最新发现,强调 TLR 在不同疾病中的作用以及它们的天然和合成调节剂的治疗效果,并讨论未来在人类健康中利用 TLR 调节剂的前景。